About Magnesium transporter NIPA4
Magnesium transporter NIPA4 (NIPAL4) is a protein
from Homo sapiens identified by UniProt accession
Q0D2K0, 404 residues long.
MolForge cross-references it against 0 known binders and
124 disease associations.
Target properties
| Protein name | Magnesium transporter NIPA4 |
| UniProt accession | Q0D2K0 |
| Gene | NIPAL4 |
| Organism | Homo sapiens |
| Length | 404 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (124)
Diseases linked to this target (Open Targets).
- lamellar ichthyosis · score 0.70
- congenital non-bullous ichthyosiform erythroderma · score 0.69
- autosomal recessive congenital ichthyosis · score 0.47
- erythrokeratodermia variabilis · score 0.27
- FEV/FVC ratio · score 0.23
- genetic disorder · score 0.19
- congenital reticular ichthyosiform erythroderma · score 0.18
- forced expiratory volume · score 0.17
- asthma · score 0.15
- neutrophil count · score 0.15
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q0D2K0-F1 | alphafold | PREDICTED | 79.31 | — |
Amino-acid sequence (404 residues)
MELRVSNTSC ENGSLLHLYC SSQEVLCQIV NDLSPEVPSN ATFHSWQERI RQNYGFYIGL GLAFLSSFLI GSSVILKKKG LLRLVATGAT RAVDGGFGYL KDAMWWAGFL TMAAGEVANF GAYAFAPATV VTPLGALSVL ISAILSSYFL RESLNLLGKL GCVICVAGST VMVIHAPEEE KVTTIMEMAS KMKDTGFIVF AVLLLVSCLI LIFVIAPRYG QRNILIYIII CSVIGAFSVA AVKGLGITIK NFFQGLPVVR HPLPYILSLI LALSLSTQVN FLNRALDIFN TSLVFPIYYV FFTTVVVTSS IILFKEWYSM SAVDIAGTLS GFVTIILGVF MLHAFKDLDI SCASLPHMHK NPPPSPAPEP TVIRLEDKNV LVDNIELAST SSPEEKPKVF IIHS
Explore Magnesium transporter NIPA4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets